Latest Market Expansion News

Step One Clothing reported modest FY25 revenue growth amid a challenging retail environment, driven by strong UK performance and a strategic shift to balance discounting and profitability.

Hansen Technologies reported robust FY25 results, driven by strong revenue growth, strategic contract wins, and deepening AI integration. The company’s expansion in Germany and sustainability leadership further underpin its positive outlook.

Breville Group Limited reported robust FY25 results with double-digit revenue and profit growth, successfully navigating US-China tariff challenges through strategic manufacturing diversification and market expansion.

Breville Group Limited reported robust FY25 results with 10.9% revenue growth and a 10.2% rise in EBIT, underpinned by strong coffee segment performance and strategic geographic expansion. The company also advanced its sustainability agenda, achieving net zero Scope 1 and 2 emissions.

Transurban reports solid FY25 results with rising toll revenue, improved EBITDA margins, and strong free cash flow, while advancing key infrastructure projects and navigating NSW Toll Reform.

Felix Group Holdings Limited announces a strategic acquisition of Nexvia Pty Ltd to boost vendor monetisation and expand its SaaS platform capabilities, supported by a $16 million capital raise. The deal is expected to increase Felix’s pro-forma ARR by 38%, positioning the company for accelerated growth.

XRF Scientific Limited reported a record profit for FY25, driven by strong mining sector demand and international sales growth, alongside strategic acquisitions that bolster its market position.

XRF Scientific has reported a record full-year result for FY2025, with net profit rising 17% to $10.4 million and a 15% increase in its fully franked dividend. Strong global mining demand and recurring revenue streams underpin the company’s growth.

Rhythm Biosciences has announced a $3.75 million placement to accelerate the commercial launch of its ColoSTAT® cancer detection test and expand its geneType™ product suite into key markets. The capital raise includes director participation and attaching options, pending shareholder approval.

Adrad Holdings reported an 8.9% rise in FY25 sales revenue to $153.1 million despite a slight dip in EBITDA, while declaring a fully franked dividend and outlining strategic initiatives for FY26.

Lumos Diagnostics has submitted its CLIA waiver application for FebriDx® to the FDA, backed by strong clinical data and triggering significant milestone payments. Approval could expand the U.S. market opportunity fifteen-fold to over $1 billion.

Audeara Limited reports a strong start to FY26 with a 46% revenue increase driven by Australian wholesale growth and a key international partnership. The company’s global ambitions are further highlighted by multiple export award nominations.